SignalXSignalX

ANAB ANAPTYSBIO, INC

FY2025 10-K
Filed: Mar 3, 2026
Health Care
Pharmaceutical PreparationsSEC EDGAR
ANAPTYSBIO, INC Overview

ANAPTYSBIO, INC (ANAB) filed its fiscal year 2025 10-K annual report with the SEC on Mar 3, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Business model: Biopharma company focusing on clinical development and commercialization collaborations, recognizing revenue mainly from milestones and royalties, not product sales
  • • New monetization deals in 2024: Sold additional Jemperli royalty receivables for $50M, expanding prior $250M monetization agreement with Sagard
+3 more insights

Risk Factors

  • • FDA acceptance of Vanda's imsidolimab BLA for GPP with target action date December 12, 2026, creating regulatory milestone risk
  • • Exposure to global macroeconomic shifts impacting 424-patient rosnilimab Phase 2b RA trial conducted worldwide
+3 more insights

Get deeper insights on ANAPTYSBIO, INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available